Aurobindo Pharma receives US FDA nod for epilepsy drug levetiracetam
The approved product has an estimated annual market size of $ 32 million in the US
 "Aurobindo Pharma receives US FDA nod for epilepsy drug levetiracetam")
premium
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (FDA) to manufacture and market levetiracetam in sodium chloride injection, 500 mg/100 mL (5 mg/mL), 1000 mg/100 mL (10 mg/mL), and 1500 mg/100 mL (15 mg/mL). The approved product is a generic equivalent of HQ Specialty Pharma Corp’s levetiracetam in sodium chloride injection. The product is expected to be launched this month.